RE:RE:Too Funny...They just raised $45M and if you look at the biotech investors mentioned in the press release who invested in the last round they have over $400B AUM so im sure they will be fine to access the capital they need. They have a more strategic investor base than Compass at this point.
With these numbers only MindMed has slightly more cash in the till and they are working on multiple trials. In most cases after you get past a phase 2 that is when you invite big pharma in on a partnership to progress phase 3.
show me any biotech / pharma company that does not burn through a whack load of cash to progress clinical trials. My comment with Cybin is they need to get on Nasdaq to really get the value, this Canadian market does not price biotech like the US does.